BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 5, 2002
View Archived Issues
With DN-101 In Phase II/III Trial, Novacea Closes $36M Series B
Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today)
Read More
Alexion Data Point To Potential For Treatment Over Long Term
Read More
Zinc-Finger Transcription Factor Switches On Body's Gene For Expression Of Multiple Proteins
Read More
FDA Tells Biogen To Clean Up Avonex Advertising Claims
Read More
Gilead Presents Combination Hepsera, Lamivudine Data
Read More
Other News To Note
Read More